The Effect of Obesity on Growth Hormone Response to Anaerobic Exercise

Obesity Clinical Trial

Official title:

The Effect of Obesity on Growth Hormone Response to Anaerobic Exercise

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT01070589
• Other study ID #: MMC01922009CTIL
• Status: Recruiting
• Phase: N/A
• First received: February 17, 2010
• Last updated: March 16, 2012
• Start date: February 2010
• Est. completion date: July 2012

Study information

• Verified date: March 2012
• Source: Meir Medical Center
• Contact: Noa rakover klein, MD
• Phone: 972-77-4920014
• Email: noa.rakover[@]gmail.com
• Is FDA regulated: No
• Health authority: Israel: Ministry of Health
• Study type: Observational

Clinical Trial Summary

The aim of the present study is to asses the effect of obesity on anaerobic exercise's growth hormone (GH) response.

Description:

Exercise is a potent physiological stimulator of growth hormone (GH) release. GH is an important factor in the distribution of fat and lean tissue in the body. Previous studies suggested that the GH response to aerobic exercise may be attenuated by obesity. The effect of obesity on GH response to anaerobic effort is unclear. The aim of the present study is to asses the effect of obesity on anaerobic exercise's GH response. We will recruit 12 obese (BMI > 30) healthy adults and 12 age and gender matched normal weight (BMI < 25) controls. All the participants will conduct a "wingate" anaerobic test (30 seconds of intense effort against resistance calculated by the individual's body weight). Blood sample for GH level will be collected at 5 different time (0, 20, 30, 40 and 60 minutes after the test). We will compare the GH response in the two groups.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 24
• Est. completion date: July 2012
• Est. primary completion date: July 2012
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: Female
• Age group: 18 Years to 40 Years

Eligibility

Inclusion Criteria:

• Healthy female

• Age 18-40

Exclusion Criteria:

• Male

• Age <18, >40

• Heart, Liver, Kidney or Hypophyseal disease

• Medications that may alter GH secretion (eg Steroids, Eltroxin)

Study Design

Observational Model: Case Control, Time Perspective: Prospective

Related Conditions & MeSH terms

• Obesity

Locations

Country	Name	City	State
Israel	Meir Medical Center	Kfar Saba

Sponsors (1)

Lead Sponsor	Collaborator
Meir Medical Center

Country where clinical trial is conducted

Israel,